China Pharma Holdings Completes $5 Million Registered Direct Offering
China Pharma Holdings, Inc. has closed a registered direct offering of its common stock, raising $5 million in gross proceeds. The company intends to use the funds for working capital and general corporate purposes.
China Pharma Holdings, Inc., a specialty pharmaceutical company based in China, announced on July 23, 2026, the closing of its previously announced registered direct offering. The offering resulted in the sale of 2,500,000 shares of common stock at a purchase price of $2.00 per share, generating $5 million in gross proceeds before deducting placement agent fees and other expenses.
The company plans to allocate the net proceeds from this offering towards strengthening its working capital and for general corporate matters. The transaction marks a significant step in the company's financial strategies for operational continuity and potential expansion.
FT Global Capital, Inc. served as the exclusive placement agent for this offering. The sale was conducted under the company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC).
China Pharma Holdings develops, manufactures, and markets a range of pharmaceutical products primarily for conditions with high incidence and mortality rates within China, including cardiovascular, central nervous system (CNS), infectious, and digestive diseases. The company operates a broad distribution network across China.